An oral ET(A)-selective endothelin receptor antagonist for contrast nephropathy?
Haylor
J L
JL
Sheffield Kidney Institute, Department of Diagnostic Imaging, Northern General Hospital, Sheffield, UK.
Morcos
S K
SK
D001794:Blood Pressure / Q000187:drug effects; D003287:Contrast Media / Q000009:adverse effects*; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1 / Q000097:blood; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006801:Humans; D007189:Indans / Q000494:pharmacology* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000139:chemically induced* / Q000188:drug therapy* / Q000503:physiopathology; D044022:Receptor, Endothelin A
D003287:Contrast Media; D065128:Endothelin Receptor Antagonists; D019332:Endothelin-1; D007189:Indans; D044022:Receptor, Endothelin A; C087551:1H-Indene-2-carboxylic acid, 1-(1,3-benzodioxol-5-yl)-3-(2- (carboxymethoxy)-4-methoxyphenyl)-2,3-dihydro-5-propoxy-, (1S,2R,3S)-